Nigerian vaccinologist presents possible experimental vaccine for disease at scientific conference

According to a statement from Dr Yuri Nakamoto on behalf of the scientific committee of the conference organised by the Pasteur Institute, Paris, as reported by Guardian, the report was one of the items discussed at the two-day conference.

The researchers were quoted as saying that they had developed and evaluated an EBOV candidate vaccine that was highly immunogenic in mice.

According to the group,

“Given the immediate need for an Ebola vaccine and the efficiency, safety and adaptability of our VLP platform technology, we are confident in producing a high yield, high quality product using the most cost effective methodologies available,’’

They stated that the vaccine approach could be used for mass vaccination in Africa to prevent EBOV infections and future epidemics of the deadly disease, adding that they were also using their platform technology to develop vaccines against HIV, malaria and other diseases that plague Africa.

The International Conference on Targeting Ebola had more than 300 delegates from 42 countries in attendance.

According to Nakamoto, the agenda of the conference included 140 oral, short and posters communications, latest developments in the Ebola outbreak in Africa, and latest clinical developments.

The presentation titled, ‘Construction and Evaluation of a Highly Immunogenic EBOLA Influenza VLP Vaccine Candidate’ was made by Agwale, alongside Epie E. and Pushko P. of Innovative Biotech Ltd, Keffi, Nasarawa State, and Innovative Biotech USA Inc.